{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:43:07Z","timestamp":1790772187151,"version":"4.1.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":1439,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"HEMA Biologics"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1111\/jth.14296","type":"journal-article","created":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T18:07:13Z","timestamp":1538158033000},"page":"2362-2374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["The future of bypassing agents for hemophilia with inhibitors in the era of novel agents"],"prefix":"10.1016","volume":"16","author":[{"given":"A.D.","family":"Shapiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5749-2200","authenticated-orcid":false,"given":"I.S.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Nasr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.14296_bb0010","first-page":"468","article-title":"Use of prothrombin complex concentrates (PCC) in hemophiliacs with inhibitors: Lack of correlation between clinical response and laboratory parameters","volume":"11","author":"Buchanan","year":"1977","journal-title":"Pediatr Res"},{"key":"10.1111\/jth.14296_bb0015","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.2830470312","article-title":"Inhibitors in hemophilia patients: current status and management","volume":"47","author":"Aledort","year":"1994","journal-title":"Am J Hematol"},{"key":"10.1111\/jth.14296_bb0020","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/hae.13301","article-title":"PERSEPT 1: a phase 3 trial of activated eptacog beta for on\u2010demand treatment of haemophilia inhibitor\u2010related bleeding","volume":"23","author":"Wang","year":"2017","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14296_bb0025","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/jth.12458","article-title":"Recommendations for performing thromboelastography\/thromboelastometry in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Chitlur","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14296_bb0030","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1097\/MBC.0000000000000137","article-title":"Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors","volume":"25","author":"Qi","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/jth.14296_bb0035","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/hae.12621","article-title":"Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on\u2010demand with bypass treatment","volume":"21","author":"Earnshaw","year":"2015","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14296_bb0040","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2516.2006.01379.x","article-title":"The history of FEIBA: a lifetime of success in the treatment of haemophilia complicated by an inhibitor","volume":"12","author":"Negrier","year":"2006","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14296_bb0045","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2147\/JBM.S61859","article-title":"Mixing and administration times of bypassing agents: observations from the Dosing Observational Study in Hemophilia (DOSE)","volume":"5","author":"Maahs","year":"2014","journal-title":"J Blood Med"},{"key":"10.1111\/jth.14296_bb0050","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/MBC.0000000000000525","article-title":"Global Post\u2010Authorization Safety Surveillance Study: real\u2010world data on prophylaxis and on\u2010demand treatment using FEIBA (an activated prothrombin complex concentrate)","volume":"27","author":"Negrier","year":"2016","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/jth.14296_bb0055","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1182\/blood.V61.1.36.36","article-title":"The use of factor eight inhibitor by\u2010passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors","volume":"61","author":"Hilgartner","year":"1983","journal-title":"Blood"},{"key":"10.1111\/jth.14296_bb0060","unstructured":"Shire. FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR). 2017. Available from: http:\/\/www.shiretrials.com\/sitecore\/content\/studies\/clinicaltrialsen\/2017\/11\/21\/10\/36\/091501?sc_lang=en. Accessed 12 February 2018."},{"key":"10.1111\/jth.14296_bb0065","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1365-2516.2007.01601.x","article-title":"Single 270 microg kg(\u20101)\u2010dose rFVIIa vs. standard 90 microg kg(\u20101)\u2010dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison","volume":"14","author":"Young","year":"2008","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14296_bb0070","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1365-2516.2008.01968.x","article-title":"Single\u2010dose (270 microg kg(\u20101)) recombinant activated factor VII for the treatment and prevention of bleeds in haemophilia A patients with inhibitors: experience from seven European haemophilia centres","volume":"15","author":"Pan\u2010Petesch","year":"2009","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14296_bb0075","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1365-2516.2009.02007.x","article-title":"Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic","volume":"15","author":"Salaj","year":"2009","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14296_bb0080","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1160\/TH05-07-0510","article-title":"Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi\u2010centre, randomised, double\u2010blind, cross\u2010over trial","volume":"95","author":"Kavakli","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14296_bb0085","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1538-7836.2006.01772.x","article-title":"A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors","volume":"4","author":"Santagostino","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"Suppl. 1","key":"10.1111\/jth.14296_bb0090","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0268-960X(15)30006-0","article-title":"Safety update on the use of recombinant activated factor VII in approved indications","volume":"29","author":"Neufeld","year":"2015","journal-title":"Blood Rev"},{"key":"10.1111\/jth.14296_bb0095","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2516.2011.02612.x","article-title":"On\u2010demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII","volume":"18","author":"Sorensen","year":"2012","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14296_bb0100","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1365-2516.2008.01956.x","article-title":"Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta\u2010regression","volume":"15","author":"Treur","year":"2009","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14296_bb0105","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood-2006-04-017988","article-title":"A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study","volume":"109","author":"Astermark","year":"2007","journal-title":"Blood"},{"key":"10.1111\/jth.14296_bb0110","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/hae.13357","article-title":"Safety and dose\u2010dependency of eptacog beta (activated) in a dose escalation study of non\u2010bleeding congenital haemophilia A or B patients, with or without inhibitors","volume":"23","author":"Ducore","year":"2017","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14296_bb0115","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2516.2004.00924.x","article-title":"Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life\u2010threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor","volume":"10","author":"Hayashi","year":"2004","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14296_bb0120","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1365-2516.2010.02467.x","article-title":"Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors","volume":"17","author":"Gringeri","year":"2011","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14296_bb0125","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2516.2007.01451.x","article-title":"Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience","volume":"13","author":"Schneiderman","year":"2007","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14296_bb0130","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1055\/s-0037-1613155","article-title":"Possible synergy between recombinant factor VIIa and prothrombin complex concentrate in hemophilia therapy","volume":"88","author":"Key","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14296_bb0135","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1055\/s-0037-1613110","article-title":"Pulmonary embolism after sequential use of recombinant factor VIIa and activated prothrombin complex concentrate in a factor VIII inhibitor patient","volume":"87","author":"Rosenfeld","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14296_bb0140","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.thromres.2012.08.305","article-title":"PRO\u2010PACT: retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors","volume":"130","author":"Young","year":"2012","journal-title":"Thromb Res"},{"key":"10.1111\/jth.14296_bb0145","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/hae.12390","article-title":"Prophylaxis with anti\u2010inhibitor coagulant complex improves health\u2010related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study","volume":"20","author":"Stasyshyn","year":"2014","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14296_bb0150","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1056\/NEJMoa1104435","article-title":"Anti\u2010inhibitor coagulant complex prophylaxis in hemophilia with inhibitors","volume":"365","author":"Leissinger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14296_bb0155","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2516.2008.01654.x","article-title":"Secondary prophylaxis with recombinant activated factor VII improves health\u2010related quality of life of haemophilia patients with inhibitors","volume":"14","author":"Hoots","year":"2008","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14296_bb0160","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1111\/j.1538-7836.2007.02663.x","article-title":"Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors","volume":"5","author":"Konkle","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14296_bb0165","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1046\/j.1365-2516.2003.00771.x","article-title":"Long\u2010term FEIBA prophylaxis does not prevent progression of existing joint disease","volume":"9","author":"Hilgartner","year":"2003","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14296_bb0170","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/hae.12602","article-title":"Prophylaxis with FEIBA in paediatric patients with haemophilia A and inhibitors","volume":"21","author":"Ewing","year":"2015","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14296_bb0175","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2516.2006.01284.x","article-title":"A retrospective postlicensure survey of FEIBA efficacy and safety","volume":"12","author":"Dimichele","year":"2006","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14296_bb0180","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2516.2007.01442.x","article-title":"Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors","volume":"13","author":"Leissinger","year":"2007","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14296_bb0185","series-title":"Biotechnology of Blood Proteins","first-page":"131","article-title":"Three year experience with plasma derived factor VIIa concentrate","author":"Verroust","year":"1993"},{"key":"10.1111\/jth.14296_bb0190","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1600-0609.1998.tb01103.x","article-title":"Early treatment with recombinant factor VIIa results in greater efficacy with less product","volume":"63","author":"Lusher","year":"1998","journal-title":"Eur J Haematol Suppl"},{"key":"10.1111\/jth.14296_bb0195","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/hae.12156","article-title":"Results of the WIRK prospective, non\u2010interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders","volume":"19","author":"Birschmann","year":"2013","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14296_bb0200","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2516.2009.02179.x","article-title":"The value of early treatment in patients with haemophilia and inhibitors","volume":"16","author":"Kavakli","year":"2010","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14296_bb0205","doi-asserted-by":"crossref","first-page":"13583","DOI":"10.1073\/pnas.241339498","article-title":"Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity","volume":"98","author":"Persson","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl. 1","key":"10.1111\/jth.14296_bb0210","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0268-960X(03)90000-2","article-title":"A cell\u2010based model of coagulation and the role of factor VIIa","volume":"17","author":"Hoffman","year":"2003","journal-title":"Blood Rev"},{"key":"10.1111\/jth.14296_bb0215","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1055\/s-0037-1615947","article-title":"A cell\u2010based model of hemostasis","volume":"85","author":"Hoffman","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14296_bb0220","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood-2011-11-393371","article-title":"Unifying the mechanism of recombinant FVIIa action: dose dependence is regulated differently by tissue factor and phospholipids","volume":"120","author":"Shibeko","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.14296_bb0225","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/jth.12628","article-title":"Predicting dosing advantages of factor VIIa variants with altered tissue factor\u2010dependent and lipid\u2010dependent activities","volume":"12","author":"Shibeko","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14296_bb0230","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/bloodadvances.2016004143","article-title":"Factor VIIa interaction with EPCR modulates the hemostatic effect of rFVIIa in hemophilia therapy: mode of its action","volume":"1","author":"Keshava","year":"2017","journal-title":"Blood Adv"},{"key":"10.1111\/jth.14296_bb0235","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1160\/TH11-09-0672","article-title":"Factor VIIa binding to endothelial cell protein C receptor: differences between mouse and human systems","volume":"107","author":"Sen","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14296_bb0240","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1182\/blood-2014-04-567297","article-title":"The endothelial protein C receptor enhances hemostasis of FVIIa administration in hemophilic mice in\u00a0vivo","volume":"124","author":"Pavani","year":"2014","journal-title":"Blood"},{"key":"10.1111\/jth.14296_bb0245","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1111\/j.1538-7836.2012.04917.x","article-title":"Endothelial cell protein C receptor\u2010mediated redistribution and tissue\u2010level accumulation of factor VIIa","volume":"10","author":"Clark","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14296_bb0250","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/bjh.14149","article-title":"In vitro uptake of recombinant factor VIIa by megakaryocytes with subsequent production of platelets containing functionally active drug","volume":"178","author":"Schut","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.14296_bb0255","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1182\/blood-2010-09-310706","article-title":"Factor VIIa bound to endothelial cell protein C receptor activates protease activated receptor\u20101 and mediates cell signaling and barrier protection","volume":"117","author":"Sen","year":"2011","journal-title":"Blood"},{"key":"10.1111\/jth.14296_bb0260","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bcmd.2015.11.004","article-title":"Heterozygous congenital Factor VII deficiency with the 9729del4 mutation, associated with severe spontaneous intracranial bleeding in an adolescent male","volume":"57","author":"Cramer","year":"2016","journal-title":"Blood Cells Mol Dis"},{"key":"10.1111\/jth.14296_bb0265","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1365-2516.2009.02121.x","article-title":"Effect of glycoPEGylation on factor VIIa binding and internalization","volume":"16","author":"Sen","year":"2010","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14296_bb0270","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1111\/j.1538-7836.2011.04344.x","article-title":"Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects","volume":"9","author":"Moss","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14296_bb0275","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/jth.12237","article-title":"40K glycoPEGylated, recombinant FVIIa: 3\u2010month, double\u2010blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors","volume":"11","author":"Ljung","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14296_bb0280","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/hae.13110","article-title":"Kinetic analysis and binding studies of a new recombinant human factor VIIa for treatment of haemophilia","volume":"23","author":"Grandoni","year":"2017","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14296_bb0285","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1093\/glycob\/cwt085","article-title":"N\u2010\/O\u2010glycosylation analysis of human FVIIa produced in the milk of transgenic rabbits","volume":"23","author":"Chevreux","year":"2013","journal-title":"Glycobiology"},{"key":"10.1111\/jth.14296_bb0290","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1111\/jth.13141","article-title":"Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity","volume":"13","author":"Mahlangu","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14296_bb0295","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/hae.12994","article-title":"TRUST trial: BAY 86\u20106150 use in haemophilia with inhibitors and assessment for immunogenicity","volume":"22","author":"Mahlangu","year":"2016","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14296_bb0300","unstructured":"Catalyst Biosciences. Catalyst Biosciences Initiates Phase 2\/3 Trial of Marzeptacog Alfa (activated) for Prophylaxis in Hemophilia A or B with Inhibitors [Press release]. South San Francisco, CA, 2018. Available from: http:\/\/ir.catalystbiosciences.com\/phoenix.zhtml?c=254141&p=irol-newsArticle_print&ID=2324884. Accessed 4 January 2018."},{"key":"10.1111\/jth.14296_bb0305","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood.V126.23.2269.2269","article-title":"Platelet\u2010targeted rFVIIa\u2010xten improves thrombin generation and fibrin formation compared to recombinant FVIIa","volume":"126","author":"Aleman","year":"2015","journal-title":"Blood"},{"key":"10.1111\/jth.14296_bb0310","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1182\/blood.V120.21.1114.1114","article-title":"Factor VIIa\u2010CTP, a novel long\u2010acting coagulation factor, displays a prolonged hemostatic effect and augmented pharmacokinetics and pharmacodynamics following IV and SC administration in hemophilic animal models","volume":"120","author":"Hart","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.14296_bb0315","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/jth.12477","article-title":"Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa\u2010FP)","volume":"12","author":"Zollner","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14296_bb0320","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2165\/11530550-000000000-00000","article-title":"Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy","volume":"24","author":"Sola","year":"2010","journal-title":"BioDrugs"},{"key":"10.1111\/jth.14296_bb0325","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1111\/jth.14204","article-title":"In\u2010depth comparison of N\u2010glycosylation of human plasma\u2010derived factor VIII and different recombinant products: from structure to clinical implications","volume":"16","author":"Canis","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14296_bb0330","unstructured":"US Department of Health and Human Services. Food and Drug Administration. FDA approves emicizumab\u2010kxwh for prevention and reduction of bleeding in patients with hemophilia A with factor VIII inhibitors. 2017. Available from: https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm585650.htm. Accessed 21 December 2017."},{"key":"10.1111\/jth.14296_bb0335","unstructured":"Roche. European Commission approves Roche's Hemlibra for people with haemophilia A with inhibitors [Press release]. Basel, Switzerland, 2018. Available from: https:\/\/www.roche.com\/media\/store\/releases\/med-cor-2018-02-27.htm. Accessed 14 May 2018."},{"key":"10.1111\/jth.14296_bb0340","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14296_bb0345","unstructured":"Genentech. Hemlibra\u00ae (emicizumab\u2010kxwh) Update. 2018. Available from: https:\/\/www.hemophilia.org\/sites\/default\/files\/article\/documents\/Genentech%20Statement%20on%20Hemlibra%20Safety%203-28-18%20%28003%29.pdf. Accessed 13 May 2018."},{"key":"10.1111\/jth.14296_bb0350","unstructured":"National Hemophila Foundation. Hemlibra safety update. 2018. Available from: https:\/\/www.hemophilia.org\/Newsroom\/Hemlibra-Safety-Update. Accessed 4 June 2018."},{"key":"10.1111\/jth.14296_bb0355","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1056\/NEJMc1712683","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors [Letter to the editor]","volume":"377","author":"Aledort","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14296_bb0360","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2516.2007.01594.x","article-title":"Factor VIII inhibitor bypassing activity (FEIBA) \u2010 addressing safety issues","volume":"14","author":"Aledort","year":"2008","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14296_bb0365","unstructured":"Genentech USA Inc. Our commitment to safety communication. 2018. Available from: https:\/\/www.emicizumabinfo.com\/. Accessed 25 July 2018."},{"key":"10.1111\/jth.14296_bb0370","first-page":"11","article-title":"In vitro thrombin generation testing and in\u00a0vivo venous stasis model for assessing the pro\u2010coagulant effects of FVIII, emicizumab, rFVIIa, and aPCC [Abstract]","volume":"23","author":"Adamkewicz","year":"2017","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14296_bb0375","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/jth.14203","article-title":"In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents","volume":"16","author":"Hartmann","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14296_bb0380","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1538-7836.2010.04152.x","article-title":"Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patients","volume":"9","author":"Agerso","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14296_bb0385","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2796.1992.tb00546.x","article-title":"Twenty\u2010five years\u2019 experience of prophylactic treatment in severe haemophilia A and B","volume":"232","author":"Nilsson","year":"1992","journal-title":"J Intern Med"},{"key":"10.1111\/jth.14296_bb0390","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco\u2010Johnson","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14296_bb0395","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1111\/jth.13811","article-title":"Effect of late prophylaxis in hemophilia on joint status: a randomized trial","volume":"15","author":"Manco\u2010Johnson","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14296_bb0400","unstructured":"Pasi KJ, Georgiev P, Mant T, Creagh MD, Lissitchkov T, Bevan D, Austin S, Hay C, Hegemann I, Kazmi R, Chowdary P, Rangarajan S, Soh C\u2010H, Monpara A, Nguyen HV, Madigan K, Ragni MV. Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: Interim Results from a Phase 2 Extension Study in Patients with Hemophilia A or B with and without Inhibitors. International Society on Thrombosis and Haemostasis (ISTH) Congress. Berlin, Germany, 2017. Available from: http:\/\/www.alnylam.com\/wp-content\/uploads\/2017\/07\/ISTH-2017_Pasi_Fitusiran-OLE_CAPELLA-Deck_vFINAL_2017.07.10.pdf. Accessed 1 August 2018."},{"key":"10.1111\/jth.14296_bb0405","unstructured":"Alnylam Pharmaceuticals. Alnylam Provides Pipeline Update on Fitusiran and Givosiran Investigational RNAi Therapeutic Programs [Press release]. Cambridge, MA, 2017. Available from: http:\/\/files.shareholder.com\/downloads\/ABEA-430HSO\/5461606227x0x955995\/B4EF879F-1426-480F-859C-1998131153F2\/ALNY_News_2017_9_7_Alnylam.pdf. Accessed 1 August 2018."},{"key":"10.1111\/jth.14296_bb0410","unstructured":"Alnylam Pharmaceuticals. Alnylam Announces Successful Outcome Following FDA Type A Meeting to Discuss Fitusiran Program in Hemophilia [Press release]. Cambridge, MA, 2017. Available from: http:\/\/investors.alnylam.com\/news-releases\/news-release-details\/alnylam-announces-successful-outcome-following-fda-type-meeting. Accessed 9 November 2017."},{"key":"10.1111\/jth.14296_bb0415","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S0049-3848(16)30359-0","article-title":"Targeting TFPI for hemophilia treatment","volume":"141","author":"Peterson","year":"2016","journal-title":"Thromb Res"},{"key":"10.1111\/jth.14296_bb0420","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/hae.13260","article-title":"Concizumab, an anti\u2010tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay","volume":"23","author":"Waters","year":"2017","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14296_bb0425","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/jth.12864","article-title":"Safety and pharmacokinetics of anti\u2010TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial","volume":"13","author":"Chowdary","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14296_bb0430","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s40265-018-0922-6","article-title":"Inhibition of tissue factor pathway inhibitor (TFPI) as a treatment for haemophilia: rationale with focus on concizumab","volume":"78","author":"Chowdary","year":"2018","journal-title":"Drugs"},{"key":"10.1111\/jth.14296_bb0435","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1182\/blood.V128.22.1401.1401","article-title":"Concizumab promotes hemostasis via a TF\u2010FVIIa dependent mechanism as shown in a rabbit hemophilia bleeding model","volume":"128","author":"Lauritzen","year":"2016","journal-title":"Blood"},{"key":"10.1111\/jth.14296_bb0440","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.thromres.2009.11.003","article-title":"Factor V Leiden and hemophilia","volume":"125","author":"Franchini","year":"2010","journal-title":"Thromb Res"},{"key":"10.1111\/jth.14296_bb0445","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/blood-2016-05-718635","article-title":"Design and characterization of an APC\u2010specific serpin for the treatment of hemophilia","volume":"129","author":"Polderdijk","year":"2017","journal-title":"Blood"},{"key":"10.1111\/jth.14296_bb0450","doi-asserted-by":"crossref","unstructured":"Oldenburg J, Mahlangu J, Bujan W, Trask P, von Mackensen S, Callaghan M, Young G, Asikanius E, Peyvandi F, Santagostino E. Emicizumab prophylaxis and health\u2010related outcomes in persons with hemophilia A (PwHA) with inhibitors: HAVEN 1 study [Abstract]. European Association for Haemophilia and Allied Disorders (EAHAD) Congress. Madrid, Spain, 2018. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/epdf\/10.1111\/hae.13393. Accessed 13 August 2018.","DOI":"10.1111\/hae.13618"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.14296","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622029427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622029427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jth.14296\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:23:08Z","timestamp":1761535388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622029427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":89,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S1538783622029427"],"URL":"https:\/\/doi.org\/10.1111\/jth.14296","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The future of bypassing agents for hemophilia with inhibitors in the era of novel agents","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.14296","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}